Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes
To evaluate the efficacy and safety of ranibizumab 0.5 mg in adult patients with macular edema (ME) resulting from any cause other than diabetes, retinal vein occlusion, or neovascular age-related macular degeneration.
Source: Ophthalmology - Category: Opthalmology Authors: Giovanni Staurenghi, Timothy Y.Y. Lai, Paul Mitchell, Sebastian Wolf, Andreas Wenzel, Jun Li, Amitabha Bhaumik, Philip G. Hykin, PROMETHEUS Study Group Tags: Original Article Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Diabetes | Endocrinology | Lucentis | Opthalmology | Ranibizumab Injection | Study | Vitamin A